Drugs / Recombinant human thyrotropin
Recombinant human thyrotropin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT00145366 | Apr 2002 → Jul 2005 | Graves disease | Odense University Hospital | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00275171 Comparator | Feb 2006 → Apr 2009 | nodular goiter | Steen Bonnema | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-06-03 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Regulatory 泽璟制药宣布递交注射用重组人促甲状腺激素生物制品上市许可申请 zelgen.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-06-03 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 泽璟制药宣布递交注射用重组人促甲状腺激素生物制品上市许可申请 zelgen.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human thyrotropin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00275171 ↗ |
| Known as | rhTSH | “Recombinant human TSH (rhTSH)” NCT00275171 ↗ |
| Known as | Thyrogen | “Recombinant human thyrotropin (Thyrogen)” NCT00145366 ↗1“Recombinant human thyrotropin (Thyrogen)” NCT00275171 ↗ |
| Action | Activate | “Stimulation with recombinant human TSH (rhTSH) before radioiodine (131I) therapy augments goiter volume reduction (GVR).” PMID 20519346 ↗ Jun 2010 |
| Route | Intramuscular | “0.1 mg rhTSH administered intramuscularly” NCT00275171 ↗ |